Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vizz

(Aceclidine ophthalmic solution)

LLENZ Therapeutics, Inc

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Presbyopia1 trial

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 3·NCT05728944·229 enrolled

Regulatory

FDA Approval Timeline[3]

Jul 31, 2025

VIZZ

NDA NDA218585

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aceclidine ophthalmic solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aceclidine ophthalmic solution compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA218585). U.S. Food & Drug Administration.
[4]
SEC EDGAR — LENZ Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: LLENZ Therapeutics, Inc

Related News